NCT04216121View on ClinicalTrials.gov

LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib

RecruitingOBSERVATIONAL
Enrollment

39

Participants

Timeline

Start Date

May 10, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Interventions
RADIATION

Local ablative therapy

Stereotactic body radiotherapy

PROCEDURE

Local ablative therapy

Surgery

Trial Locations (1)

3000

RECRUITING

UZLeuven, Leuven

All Listed Sponsors
lead

Universitaire Ziekenhuizen KU Leuven

OTHER